Alpine Immune Sc Stock Price, News & Analysis

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) reported its Q1 2022 financial results and corporate updates, revealing significant progress in its clinical pipeline. The company highlighted promising data for davoceticept, showing a 23% tumor volume reduction in evaluable participants during trials. They have also opened monotherapy expansion cohorts for patient enrollment. Financially, ALPN posted $219.1 million in cash and cash equivalents, and collaboration revenue surged to $13.6 million, up from $3.2 million a year prior. However, they recorded a net loss of $7.5 million.

Alpine Immune Sciences, Inc. (Nasdaq: ALPN) will participate in two investor conferences in May 2022. The LifeSci Partners Immunology & Inflammation Symposium is scheduled for May 10 at 3:00 p.m. ET, featuring a fireside chat. The BofA Securities Healthcare Conference 2022 will occur on May 11 at 7:15 p.m. ET, where the company will present corporately. Webcasts of both events will be accessible on their investor relations website for 90 days after the live presentations. Alpine is focused on developing innovative immunotherapies for cancer and autoimmune diseases.

Alpine Immune Sciences (NASDAQ: ALPN) reported promising results from its ongoing NEON-1 study of davoceticept, a novel immunotherapy for advanced malignancies. In a heavily pretreated cohort, 23% of participants showed tumor volume reduction. Notably, 54% achieved clinical benefit, with two partial responses observed. The treatment exhibited favorable tolerability with minimal adverse effects. Future expansion cohorts are planned for tumor types such as melanoma and renal cell carcinoma, marking a significant step in Alpine's clinical development pipeline.

Alpine Immune Sciences will host a virtual investor event on April 12th, 2022, at 6:30 p.m. ET, coinciding with the AACR Annual Meeting. The event time has changed from its original schedule. Additionally, the company will present at the 21st Annual Needham Virtual Healthcare Conference on April 13^th at 1:30 p.m. ET. Both events will be available via live webcast and can be replayed for 90 days after the presentations. For more details, visit the Alpine Immune Sciences investor relations website.

Alpine Immune Sciences (Nasdaq: ALPN) announced a publication in Nature Communications detailing the preclinical development of davoceticept, its lead immuno-oncology candidate targeting CD28 and PD-L1. The study highlights davoceticept's unique mechanism, which combines CD28 costimulation with dual checkpoint inhibition. Clinical trials, NEON-1 and NEON-2, are ongoing, with NEON-1 data to be presented at the AACR Annual Meeting on April 12. The promising results encourage continued development amidst a partial clinical hold on NEON-2.

Alpine Immune Sciences (Nasdaq: ALPN) will host a virtual investor event on April 12, 2022, at 6:00pm ET, coinciding with the AACR Annual Meeting. The event will provide a corporate update and discuss the development strategy for davoceticept (ALPN-202), including insights from its oral presentation at the meeting. Participants can join via phone or webcast, with a replay available for 90 days. Davoceticept is a first-in-class immunotherapy for cancer treatment, showing superior efficacy in preclinical studies.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced significant growth in 2021, with $176 million raised through partnerships and financing. The company is advancing three clinical-stage programs, with davoceticept phase 1 data to be presented at the 2022 AACR Annual Meeting. ALPN-303 is also progressing, with data expected in mid-2022. Financial results showed a net loss of $50.3 million for 2021, compared to $27.9 million in 2020, with a notable increase in collaboration revenue from $9.3 million in 2020 to $23.4 million in 2021. Cash and investments totaled $215.4 million as of December 31, 2021.

Alpine Immune Sciences (NASDAQ: ALPN) has announced that an abstract for the NEON-1 clinical trial results of davoceticept (ALPN-202) will be presented at the AACR Annual Meeting in New Orleans from April 8-13, 2022. This Phase 1 clinical trial focuses on the monotherapy dose escalation of davoceticept in patients with advanced malignancies. The presentation is scheduled for April 12 from 2:30 pm to 4:30 pm CDT, showcasing promising outcomes as Alpine progresses in its immunotherapy development.

Alpine Immune Sciences announced a partial clinical hold on its NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab after a Grade 5 serious adverse event, resulting in patient death. The incident was linked to potential immune-mediated myocarditis. Despite this setback, the ongoing NEON-1 trial of davoceticept as a monotherapy remains unaffected. The company emphasizes patient safety and expects to work with the FDA and partners to resume the NEON-2 trial with safety precautions after review.